As drug developers struggle to tap patients for clinical trials, software maker DecisionView says it has enhanced its product for subject enrollment planning, tracking and cost forecasting. The company announced last week the latest version of its web-based software StudyOptimizer 4.4.
In many cases, trials don't go as planned because sites aren't able to recruit patients according to schedule. With hiccups like this in mind, DecisionView has tried to make it easy for biopharma groups to analyze "the time and cost trade-offs" of their enrollment strategies. Other features of the updated software include enhancements to cost tracking, cost planning, modeling cost adjustments, support for adaptive trials and investigator scorecards.
Patient recruitment and enrollment is one of the biggest expenses for clinical trials, with drug developers mounting major outreach campaigns to get people into studies according to timelines. DecisionView's products, which are used by 8 of the 10 largest drugmakers, offer web-based technology to automate some of the steps that developers must tackle to manage enrollment.
"In planning clinical trials, patient recruitment and enrollment is a major potential source of delays," said Alan Louie, research director at IDC Health Insights, stated in DecisionView's release. "With as much as 50 percent of trial project plans requiring rescue and rework, the cost of inefficiency can be high."
- here's the release